Leading Academic and Manufacturing Organizations Join Ori Biotech’s Preferred Partner Network to Accelerate the Commercialization of Cell and Gene Therapies
18 mars 2025 09h00 HE
|
Oribiotech Ltd
Oribiotech Ltd. (Ori), announced the launch of its Preferred Partner Network (PPN), bringing together top AMCs and CDMOs.
Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema
18 mars 2025 08h02 HE
|
Ocugen
OCU200 has a very favorable safety and tolerability profileNo serious adverse events related to the study drug have been reportedDosing of the second cohort has been approved MALVERN, Pa., March 18,...
Purespring Therapeutics appoints Haseeb Ahmad as Chief Executive Officer
12 mars 2025 03h00 HE
|
Purespring Therapeutics
Haseeb Ahmad brings over 25 years of leadership experience in life sciences, most recently serving as President of Novartis Europe and will lead the Company as it advances pioneering kidney disease...
Gene Therapy Market Global Forecast to 2032: Biopharma Giants Lead Gene Therapy Market Expansion – Latest Developments & Projections
07 mars 2025 04h09 HE
|
Research and Markets
Dublin, March 07, 2025 (GLOBE NEWSWIRE) -- The "Gene Therapy Market by Type (Gene Silencing), Vector (Viral (Retroviral, AAV), Non-Viral (Oligonucleotide)), Gene Type (Receptors, Cytokine),...
Gene Therapy Collaboration and Licensing Agreements Trends Report and Directory 2024: Comprehensive Access to 770 Deals Announced Since 2016 - Upfront, Milestone, Royalties Terms
06 mars 2025 11h05 HE
|
Research and Markets
Dublin, March 06, 2025 (GLOBE NEWSWIRE) -- The "Gene Therapy Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. This report contains a...
Global Cell and Gene Therapy Manufacturing Market to Reach ~USD 10 Billion by 2032 | DelveInsight
05 mars 2025 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, March 05, 2025 (GLOBE NEWSWIRE) -- Global Cell and Gene Therapy Manufacturing Market to Reach ~USD 10 Billion by 2032 | DelveInsight The growing incidence of genetic disorders and...
Siren Biotechnology Expands Clinical and Scientific Advisory Board with Key Industry Leaders
05 mars 2025 12h15 HE
|
Siren Biotechnology, Inc.
Siren Biotechnology expands Clinical and Scientific Advisory Board with key industry leaders
Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results
05 mars 2025 07h02 HE
|
Ocugen
Reached an alignment with FDA on Phase 2/3 pivotal confirmatory clinical trial for OCU410ST for Stargardt disease potentially expediting clinical development by two to three yearsCompleted dosing in...
2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies
04 mars 2025 10h55 HE
|
Research and Markets
Dublin, March 04, 2025 (GLOBE NEWSWIRE) -- The "AAV Vectors in Gene Therapy - Pipeline Insight, 2025" report has been added to ResearchAndMarkets.com's offering.The Adeno-Associated Virus (AAV)...
Ocugen Announces Positive Opinion of EMA’s Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease
03 mars 2025 09h00 HE
|
Ocugen
MALVERN, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that...